Gamma-irradiation has been used widely to sterilize biological products. It can also be utilised as an inactivation technique to generate whole cell bacterial and viral vaccines with limited effect on pathogen structure and antigenic determinants. We have previously reported our approach to develop a cross-protective influenza A virus vaccine using gamma-irradiation (gamma-FLU) and recently reported the development of a serotype independent gamma irradiated Streptococcus pneumoniae vaccine (gamma-PN) (Babb R et al, 2016). Our published research illustrated the ability of gamma-irradiated vaccines to induce pathogen specific adaptive immune responses. We have also illustrated the ability of gamma-FLU to induce strong innate immunity, which could be used to enhance immune responses against co-administered inactivated viruses and bacteria (Babb R et al 2014 and 2017). Importantly, we have recently published the possibility of using irradiation doses as high as 50 kGy to inactivate influenza A virus without severely affecting vaccine immunogenicity (David SC et al, 2017). Furthermore, we have been investigating the possibility of using high irradiation dose to inactivate other viruses with complicated genome structure, such as rotavirus, for vaccine purposes. Our data illustrate the sterility and the immunogenicity of 50 kGy gamma-irradiated RV vaccine (gamma-RV). Overall, gamma-irradiation represents a very promising approach for development of highly effective vaccines. The high immunogenicity of materials irradiated with 50 kGy considerably expands the list of pathogens suitable for irradiation treatment for vaccine purposes.